CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
作者信息
Gregory G P, Hogg S J, Kats L M, Vidacs E, Baker A J, Gilan O, Lefebure M, Martin B P, Dawson M A, Johnstone R W, Shortt J
机构信息
1] Gene Regulation Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia [3] Monash Haematology, Monash Health, Clayton, Victoria, Australia.
1] Gene Regulation Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
出版信息
Leukemia. 2015 Jun;29(6):1437-41. doi: 10.1038/leu.2015.10. Epub 2014 Jan 12.
Abstract
摘要
相似文献
1
CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo.
Leukemia. 2015 Jun;29(6):1437-41. doi: 10.1038/leu.2015.10. Epub 2014 Jan 12.
2
Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
Sci Rep. 2017 Mar 31;7:45577. doi: 10.1038/srep45577.
3
The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Cancer Res. 2016 Mar 1;76(5):1158-69. doi: 10.1158/0008-5472.CAN-15-1070. Epub 2015 Dec 1.
4
Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Oncotarget. 2016 Aug 30;7(35):56864-56875. doi: 10.18632/oncotarget.10870.
5
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Leukemia. 2015 Aug;29(8):1702-12. doi: 10.1038/leu.2015.99. Epub 2015 Apr 17.
6
Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Cancer Biol Ther. 2011 Aug 15;12(4):314-25. doi: 10.4161/cbt.12.4.16909.
7
Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Mol Cancer Ther. 2019 Sep;18(9):1520-1532. doi: 10.1158/1535-7163.MCT-18-1023. Epub 2019 Jun 26.
8
Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
Br J Haematol. 2017 May;177(4):557-561. doi: 10.1111/bjh.14571. Epub 2017 Mar 14.
9
Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.
Oncotarget. 2015 May 20;6(14):12668-81. doi: 10.18632/oncotarget.3706.
10
Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
Oncotarget. 2015 Jun 20;6(17):14926-39. doi: 10.18632/oncotarget.3717.
引用本文的文献
1
Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues.
NPJ Precis Oncol. 2025 Jun 28;9(1):204. doi: 10.1038/s41698-025-00931-8.
2
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer.
Breast Cancer (Dove Med Press). 2025 Jun 13;17:511-521. doi: 10.2147/BCTT.S527906. eCollection 2025.
3
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress.
Nat Commun. 2025 May 28;16(1):4931. doi: 10.1038/s41467-025-60238-x.
4
The involvement of cyclin-dependent kinase 7 (CDK7) and 9 (CDK9) in coordinating transcription and cell cycle checkpoint regulation.
Cell Cycle. 2024 Nov-Dec;23(21-24):962-974. doi: 10.1080/15384101.2025.2485844. Epub 2025 Apr 14.
5
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer.
Transl Oncol. 2025 May;55:102378. doi: 10.1016/j.tranon.2025.102378. Epub 2025 Mar 30.
6
CircFUNDC1 interacts with CDK9 to promote mitophagy in nucleus pulposus cells under oxidative stress and ameliorates intervertebral disc degeneration.
Cell Death Dis. 2025 Feb 13;16(1):94. doi: 10.1038/s41419-025-07425-2.
7
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs).
Cell Death Discov. 2024 Jun 11;10(1):279. doi: 10.1038/s41420-024-02056-6.
8
CDK9 inhibition as an effective therapy for small cell lung cancer.
Cell Death Dis. 2024 May 20;15(5):345. doi: 10.1038/s41419-024-06724-4.
9
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Exp Hematol Oncol. 2024 Mar 4;13(1):27. doi: 10.1186/s40164-024-00483-w.
10
Therapeutic index of targeting select chromatin complexes in human cancer patients.
Curr Opin Genet Dev. 2024 Apr;85:102162. doi: 10.1016/j.gde.2024.102162. Epub 2024 Feb 24.
本文引用的文献
1
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.
Genes Dev. 2014 Aug 15;28(16):1800-14. doi: 10.1101/gad.244368.114.
2
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Genes Dev. 2014 Jan 1;28(1):58-70. doi: 10.1101/gad.232009.113.
3
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28.
4
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
5
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
Mol Cancer Ther. 2010 Aug;9(8):2344-53. doi: 10.1158/1535-7163.MCT-10-0324. Epub 2010 Jul 27.
6
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Blood. 2009 Oct 22;114(17):3533-7. doi: 10.1182/blood-2009-05-220095. Epub 2009 Aug 24.
7
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17961-6. doi: 10.1073/pnas.0809957105. Epub 2008 Nov 11.
8
P-TEFb is a crucial co-factor for Myc transactivation.
Cell Cycle. 2007 Aug 15;6(16):2031-7. doi: 10.4161/cc.6.16.4554. Epub 2007 Jun 5.
9
The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding.
Mol Cell Biol. 2007 Mar;27(6):2059-73. doi: 10.1128/MCB.01828-06. Epub 2007 Jan 22.
10
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Nature. 2005 Jun 2;435(7042):677-81. doi: 10.1038/nature03579. Epub 2005 May 15.
Zotero 插件